Autres langues ZyVersa Therapeutics, Inc.

Actions

ZVSA

US98987D3008

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 17/05/2024			Varia. 5j.	Varia. 1 janv.
4,487 ^USD	-7,67%		-15,02%	-50,14%

25/03	ZyVersa Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
18/03	ZyVersa Therapeutics, Inc. annonce l'approbation par l'IRB du protocole de l'essai clinique de phase 2A visant à évaluer le médiateur de l'efflux de cholestérol VAR 200 chez des patients souffrant de néphropathie diabétique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	18/03
ZyVersa Therapeutics, Inc. Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option	22/02
Jobs Data in Focus as Exchange-Traded Funds Advance, Equity Futures Mixed Pre-Bell Thursday	07/12
Top Premarket Decliners	07/12
ZyVersa Prices $5 Million Offering of Common Shares, Warrants	07/12
ZyVersa Therapeutics, Inc. Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100?s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways	06/12
Top Midday Decliners	30/11
ZyVersa Therapeutics Shares Fall Following Announcement of Reverse Stock Split, Increase in Authorized Common Shares	30/11
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock	30/11
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results	14/11
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model	09/11
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation	06/11
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	01/11
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	01/11
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	25/10/23
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	25/10/23
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function	18/10/23
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease	11/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ZyVersa Therapeutics, Inc.

Actions

ZVSA

US98987D3008

Autres langues

Filtres